- Home
- NTWK vs COEP Comparison
NTWK vs COEP Comparison
Compare NTWK & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTWK
- COEP
- Stock Information
- Founded
- NTWK 1997
- COEP 2017
- Country
- NTWK United States
- COEP United States
- Employees
- NTWK N/A
- COEP N/A
- Industry
- NTWK Computer Software: Prepackaged Software
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTWK Technology
- COEP Health Care
- Exchange
- NTWK Nasdaq
- COEP Nasdaq
- Market Cap
- NTWK 33.8M
- COEP 27.4M
- IPO Year
- NTWK 1998
- COEP N/A
- Fundamental
- Price
- NTWK $3.74
- COEP $9.47
- Analyst Decision
- NTWK
- COEP
- Analyst Count
- NTWK 0
- COEP 0
- Target Price
- NTWK N/A
- COEP N/A
- AVG Volume (30 Days)
- NTWK 26.0K
- COEP 38.0K
- Earning Date
- NTWK 05-14-2025
- COEP 08-15-2025
- Dividend Yield
- NTWK N/A
- COEP N/A
- EPS Growth
- NTWK N/A
- COEP N/A
- EPS
- NTWK 0.02
- COEP N/A
- Revenue
- NTWK $64,127,568.00
- COEP $62,874.00
- Revenue This Year
- NTWK N/A
- COEP N/A
- Revenue Next Year
- NTWK N/A
- COEP N/A
- P/E Ratio
- NTWK $180.68
- COEP N/A
- Revenue Growth
- NTWK 9.18
- COEP N/A
- 52 Week Low
- NTWK $2.14
- COEP $2.31
- 52 Week High
- NTWK $3.94
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- NTWK 86.95
- COEP 62.24
- Support Level
- NTWK $3.27
- COEP $7.25
- Resistance Level
- NTWK $3.77
- COEP $9.90
- Average True Range (ATR)
- NTWK 0.15
- COEP 0.63
- MACD
- NTWK 0.06
- COEP 0.26
- Stochastic Oscillator
- NTWK 87.50
- COEP 85.62
About NTWK NetSol Technologies Inc. Common Stock
NETSOL Technologies Inc is involved in providing information technology and enterprise software solutions. Its products and services include NFS Ascent, NFS Digital, Leasepak Cloud, Business consultancy, and information security services among others. The firm has North America, Europe, and Asia-Pacific segments, of which the majority of the revenue is derived from Asia-Pacific. It derives revenue from licensing, customization, enhancements, and maintenance of its financial applications. The company promotes and sells its products under the Netsol financial suite.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.